Transaction DateRecipientSharesTypePriceValue
22nd December 2020Partners L P/Il Bvf1,944Conversion of derivative$0.00
22nd December 2020Partners L P/Il Bvf654,215Conversion of derivative$0.00
22nd December 2020Partners L P/Il Bvf15,166Conversion of derivative$0.00
22nd December 2020Partners L P/Il Bvf97,615Conversion of derivative$0.00
22nd December 2020Partners L P/Il Bvf11,278Conversion of derivative$0.00
22nd December 2020Partners L P/Il Bvf509,410Conversion of derivative$0.00
9th December 2020Partners L P/Il Bvf166,194Open or private sale$18.00$2,991,492.00
9th December 2020Partners L P/Il Bvf239,274Open or private sale$18.00$4,306,932.00
9th December 2020Partners L P/Il Bvf25,486Open or private sale$18.00$458,748.00
2nd December 2020Israel Gp Ltd. Orbi Med103,200Open or private sale$21.60$2,229,120.00
Novus Therapeutics
Novus Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.


Novus Therapeutics Inc. engages in the acquisition, development, and commercialization of products for disorders of the ear, nose, and throat. The company's product pipelines include OPO201; OP0101; and OP0102.


Ticker: NVUS
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1404281
Employees: 8
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals